[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611548":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-XACP3","EXPERIMENTAL","Each subject receives a single intravenous injection of 68Ga-XACP3 and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET\u002FCT), 68Ga-XACP3 PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET\u002FCT), 68Ga-XACP3 PET\u002FCT","Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (68Ga-PSMA) and 68Ga-XACP3, and undergoes PET\u002FCT imaging within the specified time.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Liang Zhao","CONTACT","86 18818350620","wzhaoliang01@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Haojun Chen, MD, PhD","86 18659285282","leochen0821@foxmail.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":40,"coordinates":41},"Point",[42,43],118.08187,24.47979,{"lat":43,"lon":42},[46],{"name":23,"role":24,"phone":47,"phoneExt":20,"email":26},"86 0592-213-7366",{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100611548","68ga-xacp3-petct-in-prostate-cancer-100611548",false,"NCT07242014","68Ga-XACP3 PET\u002FCT in Prostate Cancer","PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);\n* Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET\u002FCT) and 68Ga-XACP3 PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.","MALE","18 Years","80 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"NA","The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET\u002FCT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET\u002FCT.",[68,69,70],"Prostate Cancer","PET\u002FCT","ACP3",[68,69,70],"2025-11-17",{"date":74,"type":75},"2025-11-21","ACTUAL",{"date":77,"type":75},"2025-09-01",{"date":79,"type":62},"2027-10-01",{"name":5,"class":6},1]